ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

BCTXW BriaCell Therapeutics Corporation

0,2689
0,0049 (1,86%)
28 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
BriaCell Therapeutics Corporation BCTXW NASDAQ Equity Warrant
  Änderung Änderung % Aktuell Zeit
0,0049 1,86% 0,2689 23:23:19
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,241 0,225 0,269 0,2689 0,264
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
14.6.202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14.6.202422:05EDGAR2Form 8-K - Current report
03.6.202414:00GLOBEBriaCell Presents Clinical Efficacy Data at ASCO 2024
30.5.202414:00GLOBEBriaCell Initiates Patient Enrollment in First-in-Human..
28.5.202414:00GLOBEBriaCell Announces Clinical Supply Agreement with BeiGene..
24.5.202414:58EDGAR2Form SC 13D/A - General statement of acquisition of..
24.5.202414:00GLOBEBriaCell Doubles Progression-Free-Survival (PFS) and Reports..
20.5.202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:51EDGAR2Form 8-K - Current report
17.5.202422:33GLOBEBriaCell Therapeutics Announces Closing of $5.0 Million..
16.5.202423:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15.5.202414:00GLOBEBriaCell Therapeutics Announces Pricing of $5.0 Million..
24.4.202414:00GLOBEBriaCell Announces Oral and Poster Presentations at ASCO..
10.4.202414:00GLOBEBriaCell 2024 AACR Preclinical Poster Confirms Strong..
09.4.202414:00GLOBEBriaCell Showcases Data Demonstrating Unmatched..
07.3.202414:00GLOBEBriaCell Receives and Executes Letter of Intent to Advance..
06.3.202414:00GLOBEBriaCell to Present Clinical Data in Central Nervous System..
27.2.202414:00GLOBEBriaCell Provides Update on Alleged Illegal Trading of..
07.2.202414:00GLOBEBriaCell Announces Strong Clinical Data in Breast Cancer..
06.2.202414:30GLOBEBreaking Ground in Prostate Cancer: BriaCell Announces Lead..
31.1.202404:48GLOBEBriaCell Therapeutics Corp. Announces Results of Shareholder..
04.1.202414:45GLOBEBriaCell Images Confirm Robust Anti-Tumor Activity in..
28.12.202314:55GLOBEBriaCell Reports 71% Central Nervous System Response Rate in..
20.12.202314:40GLOBEBriaCell Reports Unprecedented Preliminary Survival and..
06.12.202315:31GLOBEBriaCell Highlights Outstanding Topline Survival and..
06.12.202315:00GLOBEBriaCell 2023 SABCS Posters Confirm Activation of..
30.11.202313:00GLOBEBriaCell Records New Responder with Remarkable Improvement..
03.11.202313:31GLOBEBriaCell Reports Unprecedented Anti-Tumor Activity of its..
25.10.202315:15GLOBEBriaCell Forms Medical Advisory Board of Distinguished..
20.10.202315:15GLOBEOctober is Breast Cancer Awareness Month – BriaCell is..
18.10.202315:00GLOBEBriaCell Announces Presentations at the 2023 Society for the..
11.10.202315:10GLOBEBriaCell To Host Virtual Key Opinion Leader Event on..
04.10.202315:00GLOBEBriaCell Partners with New York Cancer & Blood Specialists..
03.10.202315:00GLOBEBriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in..
08.9.202313:00GLOBEBriaCell Reports Benchmark-Beating Patient Survival and..
31.8.202317:54GLOBEBriaCell Therapeutics Corp. Announces Closing of Plan of..
31.8.202314:21GLOBEBriaCell Accepts Letter of Intent from Weill Cornell..
25.8.202320:33GLOBEBriaCell Receives Court Approval for the Share Arrangement..
18.8.202318:21GLOBEBriaCell Therapeutics Corp. Announces Voting Results From..
16.8.202314:36GLOBEBriaCell Awarded National Cancer Institute Grant to Advance..